BioSpace News Archive

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has approved BAVENCIO® (avelumab) in combination with axitinib for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC).

MedRhythms, Inc., a Portland, Maine-based digital therapeutics company, today announced the launch of its 5-site randomized controlled trial (RCT) at the nation’s top rehabilitation hospitals and research centers to study a device that is the first product in the Company’s pipeline of digital therapeutics for neurologic disease and injury.

Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced that it has filed a prior approval supplement (PAS) for ranitidine hydrochloride injection

AEVOLVE, a medical innovation platform, is a platinum sponsor of the second annual World Crypto Conference (WCC), which will attract thousands of digital currency and blockchain technology enthusiasts to the Las Vegas strip October 29 through 31, 2019.

Healthcare workers are injured on the job more than any other profession; Excessive injuries can be prevented, and patient mobility improved with safe patient handling practices

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that Anne Sempowski Ward has joined the company’s Board of Directors, effective October 28, 2019

miRagen Therapeutics, Inc., a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs, will present an overview of its novel second generation miR-29 mimics at the DIA/FDA Oligonucleotide-Based Therapeutics Conference in Bethesda, Maryland.

Leading Innovator in Non-Invasive Pain Relief to Expand Technology in VibraCool® Flex for Low Back Pain Sufferers

Astellas Pharma Inc. announced that the U.S. Food and Drug Administration has granted Fast Track designation for the development of ASP1128 for patients at increased risk of developing moderate to severe acute kidney injury after coronary artery bypass and/or valve surgery.

EVERSANA™, the leading independent provider of commercial services to the life science industry, has been certified as a Great Place to Work® by the global authority in workplace culture.